LA JOLLA, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received positive feedback from the FDA (U.S. Food and Drug Administration) regarding MediciNova’s Phase 3 clinical development plan for MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS).